Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Laurie DeBonnett, MD, Jeremie Lincy, Julie Kanter, MD

Blood (2019) 134 (Supplement_1): 2289.

https://doi.org/10.1182/blood-2019-125868

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Miguel R. Abboud, MD, Jo Howard, MB, BChir, Rodolfo Cançado, Wally R Smith, MD, Birol Güvenç, MD, Noemi Espurz, Marine Weill, Mariane de Montalembert, MD PhD

Blood (2019) 134 (Supplement_1): 998.

https://doi.org/10.1182/blood-2019-125775

Published: 2019

Journal Articles

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Julie Kanter, MD, Darla K Liles, MD, Kim Smith-Whitley, MD, Clark Brown, MD PhD, Abdullah Kutlar, MD, Brian Elliott, Amit Shah, Jeremie Lincy, Susan Poggio, Kenneth I. Ataga, MBBS

Blood (2019) 134 (Supplement_1): 991.

https://doi.org/10.1182/blood-2019-123965

Published: 2019

Journal Articles

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Fuad A El Rassi, MD, Deepika S. Darbari, MD, Arthur Burnett, MD MBA, Jincy Paulose, MD, Dramane I Laine, Das Purkayastha, PhD, Gregory J Kato, MD

Blood (2019) 134 (Supplement_1): 1007.

https://doi.org/10.1182/blood-2019-125790

Published: 2019

Journal Articles

Mast Cells Contribute to Brain Microvascular Permeability in Sickle Cell Disease

Aditya M Mittal, Huy Tran, BSMedTech, Varun Sagi, BS, Aithanh Nguyen, Kathryn Luk, Julia Nguyen, BS, Jianxun Lei, PhD, Kalpna Gupta, PhD

Blood (2018) 132 (Supplement 1): 269.

https://doi.org/10.1182/blood-2018-99-117246

Published: 2018

Journal Articles

Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease

Ke Liu, PhD, Xiufeng Gao, MD, Jennell White, PhD, Michael U. Callaghan, MD, Patrick C. Hines, MD PhD

Blood (2018) 132 (Supplement 1): 1096.

https://doi.org/10.1182/blood-2018-99-120084

Published: 2018

Journal Articles

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Nirmish Shah, Ralph Boccia, Walter K. Kraft, Brandon M. Hardesty, Jincy Paulose, Dram Laine, Das Purkayastha, Savita Nandal, Abdullah Kutlar, MD

Blood (2018) 132 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2018-99-111332

Published: 2018

Journal Articles

Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study

Darla K Liles, MD, Rodolfo Cançado, Julie Kanter, MD, Abdullah Kutlar, MD, Andreas Bruederle, Michael Shi, MD PhD, Federico Campigotto, Kenneth I. Ataga

Blood (2018) 132 (Supplement 1): 1082.

https://doi.org/10.1182/blood-2018-99-112201

Published: 2018

Journal Articles

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Julie Kanter, MD, Brian Elliott, Denis Weber, Chiaki Tanaka, Fang Xiang, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 4782.

https://doi.org/10.1182/blood.V130.Suppl_1.4782.4782

Published: 2017

Journal Articles

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

Julie Kanter, MD, Abdullah Kutlar, MD, Darla Liles, Rodolfo Cançado, Andreas Bruederle, Michael Shi, MD PhD, Zewen Zhu, Kenneth I Ataga, MD

Blood (2017) 130 (Supplement 1): 613.

https://doi.org/10.1182/blood.V130.Suppl_1.613.613

Published: 2017

Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD

Blood (2016) 128 (22): 1.

https://doi.org/10.1182/blood.V128.22.1.1

Published: 2016

Journal Articles

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Scott A Rollins, PhD, Richard Alvarez, MBA, Ziad Kawar, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4758.

https://doi.org/10.1182/blood.V124.21.4758.4758

Published: 2014

Journal Articles

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Jonathan W. Stocker, PhD, Debra Mandarino, MD, Ziad Kawar, PhD, Richard Alvarez, MBA, David Falconer, MS, MBA, Scott A. Rollins, PhD, Russell P. Rother, PhD

Blood (2013) 122 (21): 970.

https://doi.org/10.1182/blood.V122.21.970.970

Published: 2013

NARROW

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND)

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Priapism (SPARTAN)

Mast Cells Contribute to Brain Microvascular Permeability in Sickle Cell Disease

Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only